Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00061503 · ClinicalTrials.gov registry record · Phase 4

Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension

A Phase 4 study, sponsored by Alcon Research.

Completed
Registry status
Phase 4
Development phase

NCT00061503: Completed Phase 4 study, sponsored by Alcon Research.

NCT00061503 is a Phase 4 study that has completed, run by Alcon Research. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00061503, a Phase 4 study, has completed, sponsored by Alcon Research.

COMPLETED
Registry status
Phase 4
Development phase

Study Summary

The primary objective of this study is to describe the effect of TRAVATAN 0.004% Ophthalmic Solution on aqueous humor dynamics in subjects with a clinical diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT).

Interventions

  • DRUG Travoprost

Trial Details

FieldValue
Start Date 2003-04
Est. Completion 2004-03
Phase Phase 4
Alcon Research

275 total trials

What the finished NCT00061503 record still lists

NCT00061503 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 1 intervention - of which Travoprost is the first listed.

NCT00061503 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00061503 about?

NCT00061503 is a clinical study titled "Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension". The primary objective of this study is to describe the effect of TRAVATAN 0.004% Ophthalmic Solution on aqueous humor dynamics in subjects with a clinical diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT).

What is the current status of trial NCT00061503?

This trial is currently completed. It is a Phase 4 study. The study started on 2003-04. Estimated completion is 2004-03.

What interventions are being tested in trial NCT00061503?

The interventions under investigation include: Travoprost (DRUG).

Who is sponsoring clinical trial NCT00061503?

This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00061503, the US trial registry maintained by the National Library of Medicine. NCT00061503 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.